NO20062509L - Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav - Google Patents

Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav

Info

Publication number
NO20062509L
NO20062509L NO20062509A NO20062509A NO20062509L NO 20062509 L NO20062509 L NO 20062509L NO 20062509 A NO20062509 A NO 20062509A NO 20062509 A NO20062509 A NO 20062509A NO 20062509 L NO20062509 L NO 20062509L
Authority
NO
Norway
Prior art keywords
inhibitors
present
treatment
methods
compound
Prior art date
Application number
NO20062509A
Other languages
English (en)
Norwegian (no)
Inventor
Graeme Semple
Thomas Schrader
Phillip J Skinner
Steven L Colletti
Tawfik Gharbaoui
Jason Imbriglio
Jae-Kyu Jung
Rui Liang
Subharekha Raghavan
Darby Schmidt
James R Tata
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20062509L publication Critical patent/NO20062509L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
NO20062509A 2003-10-31 2006-05-31 Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav NO20062509L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Publications (1)

Publication Number Publication Date
NO20062509L true NO20062509L (no) 2006-06-26

Family

ID=34572875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062509A NO20062509L (no) 2003-10-31 2006-05-31 Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav

Country Status (38)

Country Link
US (2) US8637555B2 (de)
EP (2) EP1599469B1 (de)
JP (2) JP4533898B2 (de)
KR (1) KR100850591B1 (de)
CN (1) CN1867562B (de)
AR (1) AR046611A1 (de)
AT (1) ATE328880T1 (de)
AU (1) AU2004287861B2 (de)
BR (1) BRPI0415631A (de)
CA (1) CA2539985C (de)
CO (1) CO5690551A2 (de)
CR (1) CR8270A (de)
CY (1) CY1105479T1 (de)
DE (1) DE602004001134T2 (de)
DK (1) DK1599469T3 (de)
EA (1) EA011484B1 (de)
EC (1) ECSP066529A (de)
ES (1) ES2267077T3 (de)
GE (1) GEP20094801B (de)
HK (1) HK1076468A1 (de)
HR (1) HRP20060286T3 (de)
IL (1) IL174042A0 (de)
IS (1) IS2372B (de)
MA (1) MA28171A1 (de)
MX (1) MXPA06004556A (de)
MY (1) MY140410A (de)
NO (1) NO20062509L (de)
NZ (1) NZ546285A (de)
PE (1) PE20050483A1 (de)
PL (1) PL1599469T3 (de)
PT (1) PT1599469E (de)
RS (1) RS20060290A (de)
SI (1) SI1599469T1 (de)
TN (1) TNSN06150A1 (de)
TW (1) TWI258478B (de)
UA (1) UA86783C2 (de)
WO (1) WO2005044816A1 (de)
ZA (2) ZA200603419B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
ES2331521T3 (es) 2003-11-21 2010-01-07 Arena Pharmaceuticals, Inc. Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo.
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
WO2006052569A1 (en) * 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006114581A1 (en) * 2005-04-28 2006-11-02 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles
JP5113046B2 (ja) 2005-06-28 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション ナイアシン受容体アゴニスト、このような化合物を含有する組成物及び治療の方法
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2872127A1 (de) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Zusammensetzungen mit statinen, biguaniden und weiteren mitteln zur verringerung des herz-kreislauf-risikos
MX2015010725A (es) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
US9975910B2 (en) 2013-07-23 2018-05-22 Eisai R&D Management Co., Ltd. Hetero-fused cyclic compound
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US20210110275A1 (en) * 2019-10-11 2021-04-15 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
PL334250A1 (en) 1996-12-23 2000-02-14 Du Pont Pharm Co Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor
US6506757B1 (en) 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN1179945C (zh) 2000-03-09 2004-12-15 小野药品工业株式会社 吲哚衍生物、其制备方法及用途
WO2003022814A1 (fr) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives d'indole
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
CA2413702A1 (en) 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
JP4102185B2 (ja) 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
WO2002094830A2 (en) 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
DE60234338D1 (de) 2001-06-01 2009-12-24 Hoffmann La Roche Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren
JP4510442B2 (ja) 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー TNF−α発現のN−ヘテロ環インヒビター
WO2003002582A1 (en) 2001-06-27 2003-01-09 Rs Tech Corp. New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
KR20040095302A (ko) 2002-03-19 2004-11-12 오노 야꾸힝 고교 가부시키가이샤 카르복실산 화합물 및 그 화합물을 유효 성분으로서함유하는 약제
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (de) 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
KR101100601B1 (ko) 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
US20070244107A1 (en) 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
WO2006052569A1 (en) 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006114581A1 (en) 2005-04-28 2006-11-02 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles

Also Published As

Publication number Publication date
JP2010163448A (ja) 2010-07-29
MY140410A (en) 2009-12-31
DK1599469T3 (da) 2006-10-09
PE20050483A1 (es) 2005-08-25
CY1105479T1 (el) 2010-07-28
EP1683794A1 (de) 2006-07-26
HRP20060286T3 (en) 2007-03-31
KR100850591B1 (ko) 2008-08-05
HK1076468A1 (en) 2006-01-20
DE602004001134D1 (de) 2006-07-20
EP1599469A1 (de) 2005-11-30
CA2539985A1 (en) 2005-05-19
SI1599469T1 (sl) 2006-10-31
EA200600879A1 (ru) 2006-10-27
EP1599469B1 (de) 2006-06-07
US20070072924A1 (en) 2007-03-29
CR8270A (es) 2006-10-06
MA28171A1 (fr) 2006-09-01
ATE328880T1 (de) 2006-06-15
BRPI0415631A (pt) 2006-12-12
JP4533898B2 (ja) 2010-09-01
TNSN06150A1 (en) 2007-11-15
ZA200606203B (en) 2007-04-25
EA011484B1 (ru) 2009-04-28
CO5690551A2 (es) 2006-10-31
IS2372B (is) 2008-06-15
US20060217562A1 (en) 2006-09-28
AU2004287861B2 (en) 2008-08-14
PL1599469T3 (pl) 2006-10-31
ZA200603419B (en) 2006-10-25
KR20060073974A (ko) 2006-06-29
WO2005044816A1 (en) 2005-05-19
DE602004001134T2 (de) 2007-04-19
IS8481A (is) 2006-05-24
IL174042A0 (en) 2006-08-01
JP2007509181A (ja) 2007-04-12
AU2004287861A1 (en) 2005-05-19
TW200530221A (en) 2005-09-16
MXPA06004556A (es) 2006-07-06
US8637555B2 (en) 2014-01-28
ES2267077T3 (es) 2007-03-01
CN1867562A (zh) 2006-11-22
AR046611A1 (es) 2005-12-14
ECSP066529A (es) 2006-10-10
RS20060290A (en) 2008-11-28
NZ546285A (en) 2010-04-30
TWI258478B (en) 2006-07-21
GEP20094801B (en) 2009-10-26
CN1867562B (zh) 2011-07-13
CA2539985C (en) 2010-02-16
UA86783C2 (ru) 2009-05-25
PT1599469E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20062509L (no) Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
NO20073766L (no) Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav
WO2004033431A3 (en) Hydroxypyrazoles for use against metabolic-related disorders
EP3129023B1 (de) Wirksame lösliche epoxidhydrolasehemmer
US9447134B2 (en) Compounds and methods for treating mammalian gastrointestinal microbial infections
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NZ587547A (en) Modulators of ATP-Binding Cassette Transporters
CA2537127A1 (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
CA2554550A1 (en) Hydroisoindoline tachykinin receptor antagonists
CA2615611A1 (en) Indazole derivatives
CA2545092A1 (en) Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
NO20084674L (no) 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
JP5765738B2 (ja) ロスバスタチンおよびアトルバスタチン誘導体
DE60327446D1 (de) 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
WO2005051937A3 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
Kato et al. Discovery of 2, 8-diazaspiro [4.5] decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension
UA90878C2 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
WO2008146917A1 (ja) リンコマイシン誘導体及びこれを有効成分とする抗菌剤
SE0403160D0 (sv) New compounds
WO2003018564A1 (fr) Inhibiteur d'acat selectif de la paroi vasculaire
TW200722522A (en) New compound colletoic acid
FR2926817A1 (fr) Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application